Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 29, 2011 Brian Orelli	Joint-Venture Acid Reflux Merck ditches its joint venture with Johnson & Johnson.
The Motley Fool November 13, 2007 Brian Orelli	Another Punch in the Nose for Pfizer The FDA clears ZYRTEC-D for over-the-counter sales; marketing of the medication will now switch hands from Pfizer to Johnson & Johnson. Investors, take note.
The Motley Fool May 12, 2004 Brian Gorman	Procter & Gamble Bets on China The consumer products powerhouse looks like it's making all the right moves.
The Motley Fool February 11, 2010 Brian Orelli	A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid.
The Motley Fool February 22, 2010 Brian Orelli	A Huge Business Wrapped Up in Tiny Packages Drug investors shouldn't forget about over-the-counter products.
The Motley Fool December 22, 2009 Brian Orelli	This Acquisition Is Icy Hot Expensive price, but Chattem may still be a good buy for sanofi-aventis.
The Motley Fool August 4, 2011 Brian Orelli	Pfizer's Long-Shot Lipitor Gamble Don't count on OTC Lipitor anytime soon.
The Motley Fool October 1, 2009 Robert Steyer	For Drugmakers, It's All In or Get Out The Solvay-Abbott deal illustrates why conglomerates are getting out of the prescription-drug business.
The Motley Fool August 25, 2009 Mike Pienciak	Will P&G Ever Turn Around? Will the recently announced sale of its pharmaceutical business to specialty-drugs developer Warner Chilcott mark a turning point for Proctor & Gamble, or just another misstep?
Reason Aug/Sep 2001 Jacob Sullum	Through the Nose An FDA advisory committee has voted overwhelmingly to recommend over-the-counter status for Claritin, Allegra, and Zyrtec, three popular prescription allergy drugs. But the drugs' manufacturers are opposing a switch, fearing that it could hurt their profits...
The Motley Fool October 27, 2004 Alyce Lomax	P&G Plows Along Investors got the jitters today, but Procter & Gamble's still strong.
The Motley Fool November 2, 2011 Brian Orelli	Lipitor Loss Looming, Pfizer Shines Good thing it's already priced in.
The Motley Fool April 13, 2006 John Reeves	A Foolish Baby Shower: Procter & Gamble Few stocks have performed as well over the long term as Procter & Gamble. Clearly, this company is built to last. Investors, take note.
The Motley Fool April 1, 2004 Bill Mann	P&G Unloads Sunny D Procter & Gamble sells its juice-based drink brand to J.W. Childs.
The Motley Fool May 12, 2011 Brian Orelli	Teva's Mixed Bag Diversification sure helps.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
The Motley Fool July 30, 2008 Brian Orelli	Teva Has Revenue in All the Wrong Places Sometimes double-digit growth isn't all it's cracked up to be. For generic-drug maker Teva Pharmaceuticals, the growth wasn't quite as exciting as the company's top line might suggest.
The Motley Fool January 26, 2006 Rich Smith	Foolish Forecast: Procter & Gamble Lathers Up If P&G continues to highlight the Household Care and Beauty businesses from the home team, and the Blades & Razors and Duracell & Braun divisions from Gillette as its star players, wise investors should give this stock a glance.
The Motley Fool January 2, 2008 Brian Orelli	Congestion in the OTC Market J&J already has generic competition for its new drug Zyrtec.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool January 22, 2010 Mike Pienciak	Can P&G Be the Amazon.com of Consumer Staples? Management hopes a new online store will boosts sales and provide consumer insight.
The Motley Fool February 17, 2010 Brian Orelli	This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it.
The Motley Fool October 30, 2009 Mike Pienciak	P&G Inches Forward Slowly, very slowly, Procter & Gamble is crawling out of consumer-staples purgatory. But don't be fooled -- the world's largest consumer products company has a long way to go before it reaches growth nirvana.
The Motley Fool January 3, 2008 Brian Orelli	8 Generic-Drug Makers for 2008 Generic-drug makers can predict the growth of their industry, because it's written right in the patent-expirations column of the FDA's orange book. Here's a brief look at eight generic-drug makers worth closer scrutiny.
The Motley Fool July 6, 2009 Mike Pienciak	Desperately Seeking Greater Growth Procter & Gamble has plenty of heft, but its growth initiatives aren't exactly inspiring.
The Motley Fool November 1, 2005 Nathan Parmelee	A Small Surprise From P&G Proctor & Gamble delivers, just like it promised, releasing first-quarter earnings that were actually a penny ahead of expectations.
The Motley Fool January 30, 2006 Stephen D. Simpson	Speed the Plough Schering-Plough is still in a precarious position, but it's likely to have above-average growth. It is also one of the few pharmaceuticals whose risk level is actually decreasing. This could be a stock worth owning for some time.
The Motley Fool June 20, 2005 Matt Thurmond	Chattem's High-Dollar Brands Health-care product maker generates big bucks from the body's annoying little problems.
The Motley Fool May 5, 2010 Brian Orelli	Teva's Double-Edged Sword Nice quarter, but where will future growth come from?
BusinessWeek February 7, 2005 Robert Berner	Welcome To Procter & Gadget The consumer giant is leading the way in building brands with mechanical gizmos
The Motley Fool August 6, 2009 Colleen Paulson	Procter & Gamble Fights the Tide Global currency fluctuations and declining volume hurt P&G's profits in the fourth quarter.
The Motley Fool January 19, 2010 Brian Orelli	Pfizer Gets Serious About Generics Serious, as in a potential $4-billion-purchase serious.
The Motley Fool November 7, 2008 Brian Orelli	Teva's Steady Growth Generic-drug maker Teva Pharmaceuticals has been a good defensive play during the severe downturn in the market.
The Motley Fool January 31, 2008 Brian Orelli	Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug.
The Motley Fool May 29, 2009 Brian Orelli	Merck's Bad News Nothing to Sneeze At The U.S. Patent and Trademark Office reexamination of Merck's patent on allergy medication, Singulair, is nothing to sneeze at. The $2.8 billion worth of Singulair that Merck sold in the U.S. last year made up 12% of its total pharmaceutical sales.
The Motley Fool April 13, 2010 Brian Orelli	Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development.
The Motley Fool January 29, 2004 Alyce Lomax	All's Wella at P&G Wella's working, but will Procter & Gamble's stake in the German company help P&G take over the world?
The Motley Fool January 8, 2010 Brian Orelli	Heartburn Relieved ... for Now AstraZeneca settles its patent dispute with Teva.
The Motley Fool February 18, 2009 Brian Orelli	Teva Raises the Barr Generic drugs are likely to be a major solution that governments use to tackle the problem of rising health-care costs, and the new, larger Teva looks well-poised to grab that growth as it happens.
The Motley Fool August 29, 2008 Brian Orelli	A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
The Motley Fool March 3, 2010 Brian Orelli	Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration.
The Motley Fool June 10, 2005 Steven Mallas	P&G's Pen Mightier Than the Stain Shareholders can count on P&G's resume when it comes to brand management and innovation. The company is leveraging its Tide brand for a smart new product.
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool October 14, 2008 Brian Orelli	Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace.
The Motley Fool January 27, 2006 Stephen D. Simpson	P&G Stocks Up on Profits Solid execution continues to be the hallmark of this consumer-goods giant. Investors, take note.
The Motley Fool May 28, 2008 Brian Lawler	No Barrier to Deals Like This In the latest example of overlap between the pharmaceutical and consumer-health care industries, Barrier Therapeutics announces that it will package one of its lead prescription drugs with a shampoo sold by Procter & Gamble.
The Motley Fool November 9, 2006 Todd Wenning	The Best Blue Chip for 2007: Procter & Gamble Investors, this omnipotent consumer staples firm is the best blue chip in the market.
The Motley Fool January 30, 2009 Colleen Paulson	It's a Big World, P&G Global currency fluctuations eat into Procter & Gamble's quarterly earnings.
The Motley Fool August 2, 2004 Phil Wohl	P&G Is No Gamble The consumer products icon produces solid growth for its fourth quarter. The shares, which carry a dividend yield of 1.92%, are a great purchase for income investors.
The Motley Fool April 7, 2010 Brian Orelli	Teva: Hold Until Things Turn Ugly Despite the drugmaker's recent success, its future looks precarious.